Biotechnology company bluebird bio has formed a broad collaboration with Celgene to develop new disease-altering gene therapies in oncology.
The multi-year research and development collaboration aims to apply gene therapy technology to modify a patient's own T-cells genetically, known as chimeric antigen receptor (CAR) T-cells, to target and destroy cancer cells.
In addition, Celgene has signed a separate strategic collaboration in the CAR T-cell field with the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children's Hospital and The Methodist Hospital, Houston, led by professor Malcolm Brenner.
Celgene, bluebird bio and Dr. Brenner's team will work together to advance and develop existing and new products and programs in the CAR T-cell field.
Bluebird bio CEO Nick Leschly said, "Celgene is a global leader in oncology and, combined with Baylor's expertise in the CAR T-cell field, we have created a great opportunity to drive innovation in a new and exciting area."
The gene therapy products currently in clinical development at bluebird bio for the treatment of childhood cerebraladrenoleukodystrophy, beta-thalassemia and sickle cell disease are independent of this collaboration, according to bluebird bio.
Financial terms of the agreement include an upfront payment and up to $225m per product in potential option fees and clinical and regulatory milestones.
